Key result
CRT in valvular heart disease yields DCM-like 1-year improvement but ischaemic-like long-term survival.
Why the study?
The effectiveness of cardiac resynchronization therapy in patients with valvular heart disease, a group not specifically investigated in randomized controlled trials, was unclear compared to patients with ischaemic heart disease or dilated cardiomyopathy.
Does cardiac resynchronization therapy (CRT) improve clinical outcomes and survival in heart failure patients with valvular heart disease compared to those with ischaemic heart disease or dilated cardiomyopathy?
Observational (n=1,480)
Yes
Does cardiac resynchronization therapy (CRT) improve clinical outcomes and survival in heart failure patients with valvular heart disease compared to those with ischaemic heart disease or dilated cardiomyopathy?
Cardiac resynchronization therapy is effective in heart failure patients with valvular heart disease, yielding clinical improvements and long-term outcomes comparable to those seen in ischaemic heart disease and dilated cardiomyopathy.
May support CRT consideration in valvular disease; extends registry data but leaves randomized confirmation open.
AIMS: To analyse the effectiveness of cardiac resynchronization therapy (CRT) in patients with valvular heart disease (a subset not specifically investigated in randomized controlled trials) in comparison with ischaemic heart disease or dilated cardiomyopathy patients. METHODS AND RESULTS: Patients enrolled in a national registry were evaluated during a median follow-up of 16 months after CRT implant. Patients with valvular heart disease treated with CRT (n = 108) in comparison with ischaemic heart disease (n = 737) and dilated cardiomyopathy (n = 635) patients presented: (i) a higher prevalence of chronic atrial fibrillation, with atrioventricular node ablation performed in around half of the cases; (ii) a similar clinical and echocardiographic profile at baseline; (iii) a similar improvement of LVEF and a similar reduction in ventricular volumes at 6-12 months; (iv) a favourable clinical response at 12 months with an improvement of the clinical composite score similar to that occurring in patients with dilated cardiomyopathy and more pronounced than that observed in patients with ischaemic heart disease; (v) a long-term outcome, in term of freedom from death or heart transplantation, similar to patients affected by ischaemic heart disease and basically more severe than that of patients affected by dilated cardiomyopathy. CONCLUSION: In 'real world' clinical practice, CRT appears to be effective also in patients with valvular heart disease. However, in this group of patients the outcome after CRT does not precisely overlap any of the two other groups of patients, for which much more data are currently available.
No takes yet. Share an insight, caveat, or question.
Boriani et al. (2009) conducted an observational in Heart failure (n=1,480). Valvular heart disease (receiving CRT) vs. Ischaemic heart disease or dilated cardiomyopathy (receiving CRT) was evaluated on Clinical composite score at 12 months and freedom from death or heart transplantation. In heart failure patients receiving CRT, those with valvular heart disease showed similar 12-month clinical improvement to dilated cardiomyopathy but long-term survival similar to ischaemic disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: